Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline.

The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday.

“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” Merck CEO Rob Davis said in a statement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In